Genentech and C3 AI Improve the Complex Biologics Manufacturing Process with AI
2024年1月31日 - 11:00PM
ビジネスワイヤ(英語)
AI insights from C3 AI Reliability increase
equipment uptime, lower maintenance costs
C3 AI (NYSE: AI), the Enterprise AI application software
company, today announced that Genentech, the medical biotechnology
company, has selected C3 AI Reliability as the continued provider
for AI-based predictive maintenance software on the company’s
biologics manufacturing equipment.
The biotechnology company began using the AI application in 2021
to ensure centrifuges in the facility remained operational, with
patients ultimately benefiting by receiving their medicines on
time. Genentech uses this facility to manufacture biologics, a
specific class of medicine that is extremely complex, time
consuming, and resource intensive to develop and deliver to
patients. These medicines help patients with some of the most
difficult to treat diseases, from multiple sclerosis and macular
degeneration to blood cancers such as lymphoma and leukemia.
“We’re proud to partner with Genentech, a company well-known for
delivering breakthrough medical innovations for patients, and
support its efforts with a robust AI program that allows what is an
involved manufacturing process to operate efficiently and ensure
patients get the care they need on time,” said C3 AI CEO Thomas M.
Siebel.
In 2022, Genentech expanded its use of C3 AI Reliability to new
assets beyond centrifuges — scaling its AI footprint to around 200
pieces of equipment total. In addition to increasing the number of
assets, the company also broadened employee training for the C3 AI
Platform, on which the predictive maintenance application runs. The
biotechnology company now has nearly 200 users — from data
scientists to facility managers — who are trained on the C3 AI
Platform and regularly use the AI application to evaluate equipment
health and maintain manufacturing operations.
About C3.ai, Inc.
C3 AI is the Enterprise AI application software company. C3 AI
delivers a family of fully integrated products including the C3 AI
Platform, an end-to-end platform for developing, deploying, and
operating enterprise AI applications, C3 AI applications, a
portfolio of industry-specific SaaS enterprise AI applications that
enable the digital transformation of organizations globally, and C3
Generative AI, a suite of large AI transformer models for the
enterprise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240131789345/en/
C3 AI Public Relations Lisa Kennedy Edelman 415-988-4960
press@c3.ai
Investor Relations
ir@c3.ai
C3 AI (NYSE:AI)
過去 株価チャート
から 4 2024 まで 5 2024
C3 AI (NYSE:AI)
過去 株価チャート
から 5 2023 まで 5 2024